BioSpace News Archive

Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical development company, is pleased to provide additional information on its interim data report for the Phase 2b part of the Company’s Phase 2b/3 clinical study of Ifenprodil for COVID-19.

Eton Pharmaceuticals, Inc. (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative treatments for rare pediatric diseases, today announced the U.S. Food and Drug Administration (FDA) has accepted for filing the company’s new drug application (NDA) for topiramate oral solution.

VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) , a specialty pharmaceutical company focused on developing and commercializing proprietary therapies to address unmet needs in dermatology, today announced the successful completion of its End-of-Phase 2 Meeting with the U.S. Food and Drug Administration (FDA).

Biosight Ltd., a pharmaceutical development company developing innovative therapeutics for hematological malignancies and disorders, today announced the European Medicines Agency (EMA) has granted Orphan Medicinal Product Designation to aspacytarabine (BST-236) for the treatment of acute myeloid leukemia (AML)

Early diagnosis and proper choice of antimicrobials are crucial for successful management of pneumonia Study demonstrates Unyvero LRT BAL provides accurate detection of common agents of bacterial pneumonia and of Pneumocystis jirovecii in ~4.5 hours Performance data, comprehensive coverage and fast time to result of this panel suggest significant clinical value for choosing appropriate antibiotics and for antibiotic stewardship

US Radiology Specialists, one of the premier physician-owned radiology operators in the country, has selected the latest innovations from Volpara Health’s Breast Health Platform to drive efficient and high quality breast imaging across the network

Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced the submission of a supplemental new drug application (sNDA) to the U.S. Food and Drug Administration (FDA) for AYVAKIT™

Rheos Medicines, a precision medicine company using insights from immunometabolism to bring novel therapeutics to patients suffering from autoimmune diseases, and PatientsLikeMe, the world’s largest integrated community, health management, and real-world data platform, today announced a strategic partnership.

Perrigo Company plc (NYSE; TASE: PRGO), today announced that EVP and President of Consumer Self-Care Americas, Rich Sorota will present at the ICR Conference at 11:30 AM EST on Monday, January 11, 2021 .

iMetabolic Biopharma Corporation (iMBP) announces expansion of its strategic partnership relationship with Ligand Pharmaceuticals, building on an earlier alliance agreement initiated in 2018, giving access to Ligand’s OmniAb platform. In this new agreement, iMBP gains access to additional OmniAb species and technologies, enabling the acceleration of iMBP’s development of assets through its iPlatform™ Technology. This stre